Literature DB >> 21628438

A subjective cognitive impairment scale for migraine attacks. The MIG-SCOG: development and validation.

Raquel Gil-Gouveia1, António G Oliveira, Isabel Pavão Martins.   

Abstract

BACKGROUND: The burden of migraine is determined by impairment during attacks due to pain or non-painful symptoms such as cognitive symptoms.
OBJECTIVE: Development of a questionnaire to measure self-reported subjective cognitive symptoms during migraine attacks.
METHODS: Item generation was accomplished through structured patient interviews analysed by a panel of experts. A set of 43 candidate items was applied to consecutive migraine patients. Test construction with factor analysis retained nine items. Internal consistency was assessed with Cronbach's alpha and Spearman's rho, and convergent and construct validity by correlation to spontaneous cognitive complaints, and the 43-item and the Cognitive Failures Questionnaires.
RESULTS: The nine-item Mig-SCog covers two domains, executive functions and language. Cronbach's alpha was 0.82. It correlates with spontaneous cognitive complaints (p < 0.001), the 43-item (rho = 0.69) and the Cognitive Failures Questionnaires (rho = 0.61). Test-retest reliability (Cohen's kappa) was 0.55.
CONCLUSIONS: Mig-SCog is a valid, reliable, consistent working instrument of fast self-administration that quantifies subjective cognitive symptoms during migraine attacks.

Entities:  

Mesh:

Year:  2011        PMID: 21628438     DOI: 10.1177/0333102411408359

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  5 in total

Review 1.  Cognition and Cognitive Impairment in Migraine.

Authors:  Raquel Gil-Gouveia; Isabel Pavão Martins
Journal:  Curr Pain Headache Rep       Date:  2019-09-11

Review 2.  Assessment of cognitive dysfunction during migraine attacks: a systematic review.

Authors:  Raquel Gil-Gouveia; António G Oliveira; Isabel Pavão Martins
Journal:  J Neurol       Date:  2014-12-27       Impact factor: 4.849

3.  Visuospatial learning is fostered in migraine: evidence by a neuropsychological study.

Authors:  Roberta Baschi; R Monastero; G Cosentino; V Costa; G Giglia; B Fierro; F Brighina
Journal:  Neurol Sci       Date:  2019-06-27       Impact factor: 3.307

4.  In search of a gold standard patient-reported outcome measure to use in the evaluation and treatment-decision making in migraine prevention. A real-world evidence study.

Authors:  Alicia Alpuente; Victor J Gallardo; Edoardo Caronna; Marta Torres-Ferrus; Patricia Pozo-Rosich
Journal:  J Headache Pain       Date:  2021-12-13       Impact factor: 7.277

5.  Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience.

Authors:  Antonio Russo; Marcello Silvestro; Fabrizio Scotto di Clemente; Francesca Trojsi; Alvino Bisecco; Simona Bonavita; Alessandro Tessitore; Gioacchino Tedeschi
Journal:  J Headache Pain       Date:  2020-06-09       Impact factor: 7.277

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.